Ossium Health, Inc.

Ossium Health, Inc. is a company in San Francisco, United States, incorporated on February 8, 2016. It has created a new paradigm for cell therapy development by bringing the deceased donor transplant ecosystem into the fight against diseases of the blood and immune systems. Ossium works closely with healthcare providers, life science companies, and organ procurement organizations to develop and deploy cell therapies, and supplies both clinical and research grade human cells. Its offerings include OssiGraft viable bone matrix allografts, GMP human mesenchymal stem cells, GMP human selected CD34+ cells, RUO mesenchymal stem cells, RUO human selected CD34+ cells, and HPC, Marrow. Ossium Health has maintained CLIA certification since 2019.

Kevin and Erik met at a conference in San Francisco in February 2015 and became fast friends. Ossium Health was incorporated on February 8, 2016, and both founders soon quit their jobs to work on Ossium full-time. In June 2017, Ossium accepted its first vertebral body donors. In May 2018, Ossium raised more than $10M in Series A funding led by First Round Capital and joined by Village Global. In January 2020, Ossium achieved Phase I GMP and banked its first clinical-grade donor, setting the stage for clinical trials. In October 2020, Ossium raised $63M in Series B funding, co-led by Vivo Capital and General Catalyst, with Manta Ray Ventures, First Round Capital, and XYZ Capital also backing the round. In November 2021, the first patient was treated with Ossium's CD34+ product in the multivisceral transplant study at Columbia University Medical Center. In July 2023, Ossium raised a $52 million Series C funding round led by CPMG, with participation from Vivo Capital, First Round Capital, Manta Ray Ventures, Alumni Ventures, and Asahi Kasei. In November 2023, the first patient was treated with OssiGraft, marking Ossium's entry into orthopedics. In June 2024, the first patient was successfully treated and engrafted with Ossium's HPC, Marrow in a bone marrow transplant at Henry Ford Health in Detroit, MI. In August 2024, Ossium began a partnership with the US Government's Biomedical Advanced Research and Development Authority (BARDA) to advance the use of HPC, Marrow for radiological and nuclear emergencies.

Ossium has created a new paradigm for cell therapy development by bringing the deceased donor transplant ecosystem into the fight against diseases of the blood and immune systems.

• OssiGraft Viable Bone Matrix Allografts

  Viable bone matrix allografts for the repair, replacement, and reconstruction of musculoskeletal defects.

• GMP Human Mesenchymal Stem Cells

  Ossium's GMP MSCs are derived from the vertebral bodies of organ donors and are phenotypically and functionally equivalent to MSCs obtained from aspirated bone marrow.

• GMP Human Selected CD34+ Cells

  Ossium's GMP CD34+ cells are aseptically selected from vertebral body bone marrow by density gradient and positive immunomagnetic separation.

• RUO Mesenchymal Stem Cells (MSCs)

  Ossium's MSCs are derived from the vertebral bodies of organ donors and are phenotypically and functionally equivalent to MSCs obtained from aspirated bone marrow. Intended for research use only.

• RUO Human Selected CD34+ Cells

  Human CD34+ cells, positively selected from HPC, Marrow and enriched for hematopoietic stem cells (HSCs). Intended for research use only.

• HPC, Marrow

  Cryopreserved whole bone marrow derived from organ donor vertebral bodies using Ossium's proprietary processing methods, contains Hematopoietic Progenitor Cells (HPCs).

1. 1Homepage - Ossium Healthossiumhealth.com
2. 2Company About - Ossium Healthossiumhealth.com
3. 3Products - Ossium Healthossiumhealth.com